CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
  
  Optimal oncologic management of ovarian cancer begins with intensive surgical staging and cytoreduction, followed by postoperative chemotherapy and, in most cases, subsequent medical management when platinum-resistant relapsed disease prevails. Although many single-agent and combination cytotoxic recurrence regimens have been studied, only recently has the advent of antibody and small-molecule growth-inhibitory targeted agents been integrated into the ovarian cancer research milieu. It is hoped that the results from these trials will lead to the emergence of new therapeutic agents and changes or enhancements in the indications for existing treatment strategies, ultimately improving the duration and quality of life for patients with metastatic ovarian cancer. In order to offer optimal care to the population of patients with ovarian cancer — including the option of clinical trial participation — practicing oncologists must be well informed of these advances. By providing access to the latest research developments and expert perspectives through one-on-one discussion with leading investigators, Ovarian Cancer Update will assist medical and gynecologic oncologists with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Consider the utility of CA125 serum levels in monitoring disease progression and making treatment decisions.
  • Compare and contrast the risks and benefits of intraperitoneal and intravenous chemotherapy regimens when devising management strategies for optimally debulked Stage II or Stage III ovarian cancer.
  • Develop an evidence-based algorithm for the systemic treatment of recurrent platinum-sensitive and platinum-resistant ovarian cancer that optimizes long-term patient outcomes and quality of life.
  • Describe emerging data on the activity of poly(ADP-ribose) polymerase (PARP) inhibitors in patients with BRCA-like advanced ovarian cancer.
  • Summarize the existing data and ongoing clinical trials focused on angiogenesis inhibition in ovarian cancer, and identify patients who may benefit from this therapeutic approach.
  • Recall the rationale and activity of novel targeted agents under investigation for the treatment of ovarian cancer.
  • Counsel appropriately selected patients with ovarian cancer about the availability of and participation in ongoing clinical trials.

  ACCREDITATION STATEMENT
  
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  
  CME credit is no longer available for this issue
  
  This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s in addition to links to relevant full-text articles, abstracts, trial information and other web resources.
  
  CONTENT VALIDATION AND DISCLOSURES
  
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  

  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Herzog — Advisory Committee: Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Pfizer Inc; Speakers Bureau: Amgen Inc. Dr Armstrong — Advisory Committee: Abraxis BioScience, Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology. Dr Burger — Advisory Committee: Pfizer Inc; Honorarium: Lilly USA LLC. Dr Ozols — Advisory Committee: Genentech BioOncology; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company; Speakers Bureau: Lilly USA LLC.
  
  EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This program is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Genentech BioOncology, Lilly USA LLC and Sanofi-Aventis.
  
  Hardware/Software Requirements:
  An Internet connection that is at least 28.8 Kbps
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
  Macromedia Flash plug-in 6.0 or greater
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: October 2010
  Expiration date: October 2011